Onco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab Ltd, has received final Abbreviated New Drug Application (ANDA) approval for Venorelbine injection USP, 10 mg/ml packaged in 10 mg/1 ml and 50 mg/5ml single dose vials.
Venorelbine is a part of the oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch.
The drug is used to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cancer cell growth.